ERBB2 and breast carcinoma: To identify miRNAs that sensitize HER2+ breast cancer cells to trastuzumab and lapatinib, we performed a high-throughput screen of 810 miRNA mimics and 816 miRNA inhibitors in KPL4 and SUM190PT cell lines treated with either of the drugs or the combination.